Abciximab and Abrocitinib: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 10, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Abrocitinib
Abciximab
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Taking abrocitinib (Cibinqo) with abciximab together can raise your risk of bleeding. Abciximab is a strong blood thinner used during certain heart procedures, and it stops platelets from sticking together to form clots. Abrocitinib can also affect platelets during your first few months on it. When both work at the same time, your blood may have a harder time clotting, so you could bruise or bleed more easily.
Because of this, using these two together in the early months of abrocitinib treatment is something doctors avoid. The good news is your care team is aware of this and can plan around it. Always let your pharmacist or doctor know about every medicine you take.
Effect: Additive antihemostatic activity increasing bleeding risk.
- Mechanism: Pharmacodynamic (additive) effect on hemostasis. Abciximab is a GPIIb/IIIa inhibitor that blocks platelet aggregation; abrocitinib (a JAK1 inhibitor) can cause thrombocytopenia and platelet effects, particularly during the first months of therapy. Neither is a prodrug relevant here.
- Direction/magnitude: Increased bleeding risk; magnitude not quantified.
- Onset: Unspecified.
- Evidence: Theoretical.
- Management: Coadministration with antiplatelet agents (other than low-dose aspirin, 81 mg/day or less) during the first 3 months of abrocitinib therapy is contraindicated. Coordinate care and consider alternatives.
What happens
Increased risk of bleeding
Interaction Deep Dive
Giving abrocitinib together with antiplatelet drugs is contraindicated throughout the initial 3 months of therapy, with the exception of low-dose aspirin (no more than 81 mg per day), because of a heightened bleeding risk1.
Why it happens (mechanism)
Additive effects on hemostasis
How to manage this interaction
What your care team may do:
- Avoid combining abrocitinib with abciximab during the first 3 months of abrocitinib treatment, since this pairing is contraindicated for bleeding risk.
- Consider an alternative plan or timing, which your prescriber will individualize.
- Note that low-dose aspirin (81 mg daily or less) is the exception that is generally allowed.
What you should do:
- Keep taking your medicines exactly as prescribed and do not stop either one on your own.
- Tell your pharmacist and doctor about both drugs so they can coordinate your care.
- Report any unusual bruising, bleeding, or dark stools right away.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Abciximab and Abrocitinib together?
Combining abrocitinib with abciximab during the first 3 months of abrocitinib treatment is contraindicated because of added bleeding risk; talk with your doctor or pharmacist before using both. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Abciximab and Abrocitinib interaction?
It is rated contraindicated. These should generally not be used together.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Abciximab and Abrocitinib interaction managed?
What your care team may do: Avoid combining abrocitinib with abciximab during the first 3 months of abrocitinib treatment, since this pairing is contraindicated for bleeding risk. Consider an alternative plan or timing, which your prescriber will individualize. Note that low-dose aspirin (81 mg daily or less) is the exception that is generally allowed. What you should do: Keep taking your medicine… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Abciximab or Abrocitinib need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: CIBINQO(TM) oral tablets, abrocitinib oral tablets. Pfizer Labs (per FDA), New York, NY, 2022. DailyMed
Keep reading about Abrocitinib
Keep reading about Abciximab
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist